Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 1
1992 2
1995 1
1996 2
1997 1
1998 2
1999 1
2001 2
2002 3
2003 1
2004 3
2005 6
2006 8
2007 7
2008 11
2009 18
2010 18
2011 13
2012 22
2013 16
2014 9
2015 12
2016 10
2017 15
2018 10
2019 12
2020 12
2021 12
2022 14
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
Pettigrew JA, Novick AM. Pettigrew JA, et al. J Midwifery Womens Health. 2021 Nov;66(6):740-748. doi: 10.1111/jmwh.13283. Epub 2021 Sep 12. J Midwifery Womens Health. 2021. PMID: 34510696 Free PMC article. Review.
Many health care providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of familiarity with treatment, or the belief that they lack adequate time to address this complex issue. This may be especially true for hypoacti …
Many health care providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of famil …
Female Sexual Dysfunction.
Clayton AH, Valladares Juarez EM. Clayton AH, et al. Med Clin North Am. 2019 Jul;103(4):681-698. doi: 10.1016/j.mcna.2019.02.008. Med Clin North Am. 2019. PMID: 31078200 Review.
Medical Treatment of Female Sexual Dysfunction.
Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Nappi RE, et al. Urol Clin North Am. 2022 May;49(2):299-307. doi: 10.1016/j.ucl.2022.02.001. Urol Clin North Am. 2022. PMID: 35428435 Review.
Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women, whereas transdermal testosterone is effective on HSDD in postmenopausal women. .. …
Flibanserin and bremelanotide are psychoactive agents indicated for the treatment of generalized acquired hypoactive sexual …
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, Park K, Stuenkel CA, Traish AM, Vignozzi L. Parish SJ, et al. J Sex Med. 2021 May;18(5):849-867. doi: 10.1016/j.jsxm.2020.10.009. Epub 2021 Apr 1. J Sex Med. 2021. PMID: 33814355 Free article. Review.
BACKGROUND: The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position Statement) recommended testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD). AIM: To provide a clin …
BACKGROUND: The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position Statement) recommended tes …
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Goldstein I, et al. Mayo Clin Proc. 2017 Jan;92(1):114-128. doi: 10.1016/j.mayocp.2016.09.018. Epub 2016 Dec 1. Mayo Clin Proc. 2017. PMID: 27916394 Free article. Review.
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual …
The objective of the International Society for the Study of Women's Sexual Health expert consensus panel was to develop a concise, clinicall …
The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review.
Uloko M, Rahman F, Puri LI, Rubin RS. Uloko M, et al. Int J Impot Res. 2022 Nov;34(7):635-641. doi: 10.1038/s41443-022-00613-0. Epub 2022 Oct 5. Int J Impot Res. 2022. PMID: 36198811 Free PMC article. Review.
As a result, many postmenopausal women experience Female Sexual Dysfunction (FSD) which are a group of disorders that pertain to sexual arousal, desire, orgasm, and pain. A prevalent manifestation of FSD is Hypoactive Sexual Desire Disorder (HSDD) or t …
As a result, many postmenopausal women experience Female Sexual Dysfunction (FSD) which are a group of disorders that pertain to sexual arou …
Sexual Performance Anxiety.
Pyke RE. Pyke RE. Sex Med Rev. 2020 Apr;8(2):183-190. doi: 10.1016/j.sxmr.2019.07.001. Epub 2019 Aug 22. Sex Med Rev. 2020. PMID: 31447414 Review.
Flibanserin.
Vallejos X, Wu C. Vallejos X, et al. J Pharm Pract. 2017 Apr;30(2):256-260. doi: 10.1177/0897190016630409. Epub 2016 Jul 9. J Pharm Pract. 2017. PMID: 26873507 Review.
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. DATA SOURCES: A literature …
OBJECTIVE: To review pivotal clinical trials, pharmacology, contraindications, precautions, and key patient education points of flibanserin …
Female Sexual Dysfunction.
Clayton AH, Valladares Juarez EM. Clayton AH, et al. Psychiatr Clin North Am. 2017 Jun;40(2):267-284. doi: 10.1016/j.psc.2017.01.004. Epub 2017 Mar 25. Psychiatr Clin North Am. 2017. PMID: 28477652 Review.
Flibanserin and its discontents.
Aftab A, Chen C, McBride J. Aftab A, et al. Arch Womens Ment Health. 2017 Apr;20(2):243-247. doi: 10.1007/s00737-016-0693-6. Epub 2016 Nov 17. Arch Womens Ment Health. 2017. PMID: 27858170 Review.
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This article summarizes and promotes discussio …
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired, generalized …
230 results